Marques Marisa B, Tuncer Hande H
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, 35249, USA.
J Clin Apher. 2006 Apr;21(1):72-7. doi: 10.1002/jca.20089.
Photopheresis has become a key component in the therapeutic armamentarium of cutaneous T-cell lymphoma, graft-versus-host disease following stem cell transplant, and allograft rejection of solid organs such as heart. Although it is considered a new treatment modality in its present form, the field of phototherapy dates back thousands of years. In this review, the reader will learn more about the history of photopheresis and how it became a therapeutic alternative for patients with solid organ transplants. An extensive literature search will highlight the evidence-based benefits of photopheresis (or lack thereof). A discussion of the mechanism of action of photopheresis and the technical aspects of the procedure will also be covered. Since photopheresis may be the best tolerated form of immunomodulation, current promising, albeit preliminary data on its efficacy warrant further investigation and understanding.
光分离置换疗法已成为皮肤T细胞淋巴瘤、干细胞移植后移植物抗宿主病以及心脏等实体器官同种异体移植排斥反应治疗手段中的关键组成部分。尽管以其目前的形式它被视为一种新的治疗方式，但光疗领域可追溯到数千年前。在这篇综述中，读者将更多地了解光分离置换疗法的历史以及它如何成为实体器官移植患者的一种治疗选择。广泛的文献检索将突出光分离置换疗法基于证据的益处（或缺乏益处的情况）。还将讨论光分离置换疗法的作用机制和该程序的技术方面。由于光分离置换疗法可能是耐受性最佳的免疫调节形式，目前关于其疗效的有前景的初步数据值得进一步研究和了解。
